Abstract
Background
This study aims to investigate the effects of iodinated contrast media (ICM) exposure on thyroid function in patients with subclinical hyperthyroidism.
Methods
The study included 46 patients with subclinical hyperthyroidism who presented to the cardiology outpatient clinic and underwent angiographic imaging procedures. Thyroid function tests (TSH, fT3, fT4) of the patients before and after the procedure were analyzed retrospectively. Patients were divided into two groups as low volume (< 200 ml) and high volume (≥ 200 ml) according to the volume of contrast medium received. Pre- and post-procedure comparisons as well as analyses according to low and high-volume exposure were performed.
Results
After the procedure, 50% of the patients became euthyroid and 41.3% remained in the same group (subclinical hyperthyroidism). 2 patients (4.3%) developed clinical hyperthyroidism, and another 2 patients (4.3%) developed clinical hypothyroidism. TSH values increased significantly after the procedure (p < 0.01), but no significant change was observed in fT3 and fT4 values.
Conclusions
In patients with subclinical hyperthyroidism, thyroid function mostly remained stable or became euthyroid after ICM exposure. However, a group of patients developed clinical hypothyroidism or hyperthyroidism. These results suggest that patients with subclinical hyperthyroidism should be closely monitored when using ICM. Long-term follow-up will contribute to a better understanding of the possible risks in this patient group.
Keywords: Subclinical hyperthyroidism, Iodinated contrast media, Angiography, Thyroid dysfunction
Introduction
The use of iodinated contrast agents (ICMs) in cardiovascular imaging modalities such as coronary angiography (CAG) is a common practice. ICMs are used to improve the quality of imaging and facilitate the diagnostic process, and there has been an increasing trend in the use of cardiovascular imaging tools, including coronary angiography, in recent years [1]. Side effects such as allergic reactions to iodinated contrast media and contrast-mediated nephropathy are well known [2, 3]. However, the effects of ICMs on thyroid functions have been debated for many years. ICMs contain an average of 300–370 mg/mL iodine. The recommended daily iodine dose is 150 µg for adults and the upper limit without side effects has been reported as 1100 µg/day. [4, 5] Although it varies according to the production time of the bottles, the average free iodine content in 200 ml doses used in coronary angiographies can be calculated as 35 µg/mL, 7000 µg in total, and this dose is approximately 45 times the daily iodine requirement [6]. In high dose iodine exposure, thyroid function begins to be affected in cases where escape from the Wolf Chaikoff effect is impaired or the Jod Basedow phenomenon is observed [7–10]. Thyroid dysfunction has been demonstrated by retrospective cohort studies at all intensities of ICM exposure [11]. Several studies have shown that different clinical pictures such as subclinical and clinical hyperthyroidism or hypothyroidism may develop after exposure to high amounts of ICM, especially cardiovascular imaging [12–15]. It has also been shown that this effect becomes more pronounced as the applied ICM volume increases [16]. Some studies have suggested that ICM exposure may cause permanent changes in thyroid hormones [17]. In the light of all these, it is thought that the clinical importance of thyroid-related pathologies related to ICMs has increased with the increasing number of cardiovascular imaging modalities.
Within the group of thyroid diseases, subclinical hyperthyroidism is a common condition observed between 1 and 2% in the general population [18, 19]. It is known to be associated with cardiovascular complications such as coronary artery disease, atrial fibrillation and even mortality [20]. Failure to predict the results of imaging with ICM in a population already at cardiovascular risk may cause clinicians to hesitate. Many studies have examined the effects of ICM in a euthyroid patient population. In contrast to previous studies, this study was retrospectively designed to evaluate the known effects of ICM exposure on thyroid function in a selected group of patients with subclinical hyperthyroidism and aims to examine the changes in thyroid function of patients according to the volume of ICM exposed.
Materials and methods
The study was conducted retrospectively on patients who required angiographic intervention in the Cardiology outpatient clinics of Dr. Siyami Ersek Thoracic Cardiovascular Surgery Training and Research Hospital between June 2023 and June 2024. The study was conducted in Istanbul, Turkey, which is considered an iodine-sufficient region according to national iodine monitoring data [21]. Patients over 18 years of age were included in the study. Among all patients, those whose thyroid function tests were not checked before the procedure and in the first month after the procedure were excluded, those with renal dysfunction (creatinine 1.5 mg/dl) were not included in the study, and among the remaining patients, patients with previously known thyroid drug use, thyroid-related drug use such as amiodarone or lithium in the group that met the definition of subclinical hyperthyroidism were excluded from the study. For the definition of subclinical hyperthyroidism, a TSH cut-off value below 5.0 mIU/L, fT3 and fT4 within the normal range (2.00-4.4 and 0.85–1.8 ng/L, respectively) were defined as criteria (Fig. 1).
Fig. 1.
Flow diagram for determining the study population
Using the hospital database, the age and gender information of the selected patients were noted, and TSH, fT3 and fT4 values measured in routine outpatient clinic controls before and in the first month after the procedure were recorded. Patients with low TSH values and fT3 and fT4 values above the normal range were included in the hyperthyroidism group; those with TSH, fT3 and fT4 values within the normal range were included in the euthyroid group; and those with TSH values above the upper limit of 5.0 mIU/L and fT4 values below the normal limit were included in the hypothyroidism group. Patients who maintained their current status continued to be analyzed in the subclinical hyperthyroidism group.
The contrast medium used (Ultravist 370, Schering AG, Berlin, Germany) is a water-soluble, non-ionic iodinated agent containing 370 mg/mL iodine. Patients with contrast media exposure of 200 ml or less with standard coronary angiography were included in the “low volume” group, and patients with contrast media exposure of 200 ml or more with special procedures such as ventriculography and right heart catheterization were included in the “high volume” group.
Statistical methods
In statistical analyses, the frequency of categorical variables was expressed as numerical values and percentages, and the chi-square test or Fisher’s exact test was used for significance between two categorical variables. Descriptive statistics for continuous variables were expressed as mean (± standard deviation) for those with normal distribution and median (min-max) for those without normal distribution. For the comparison of continuous variables before and after the procedure, paired samples t-test was used for normally distributed variables and Wilcoxin signed rank test was used for non-normally distributed variables. Two-way repeated ANOVA test was used for the comparison of the values before and after the procedure in the presence of a categorical variable factor such as volume status. All probabilities were two-way and p value was set as significance level < 0.05. SPSS 29.0 (SPSS Inc, Chicago, IL, USA) software was used for statistics.
Results
While determining the target population for the study, subclinical hyperthyroidism was found in 46 (5.6%) of 818 patients whose thyroid function values were measured before and after the procedure. Of the 46 patients included in the study, 13 (28.3%) were female and 33 (71.7%) were male. The mean age of the patients ranging between 46 and 72 years was calculated as 58.3 (± 8.51). Ventriculography and right heart catheterization were performed in 8 patients (17.4%) and standard coronary angiography was performed in the remaining 38 patients (82.6%). Due to the retrospective design of the study, the etiology of subclinical hyperthyroidism (such as Graves’ disease, toxic nodular goiter, or thyroiditis) could not be determined, since scintigraphy and autoantibody testing were not available for all patients.
All of the patients had subclinical hyperthyroidism before the procedure, but only 19 (41.3%) remained the same after the procedure. 23 (50%) became euthyroid. 2 (4.3%) developed overt clinical hyperthyroidism and 2 (4.3%) developed overt clinical hypothyroidism. There were no patients with subclinical hypothyroidism (Fig. 2).
Fig. 2.
Classification of patients according to the status of thyroid function after the procedure
TSH, fT3 and fT4 values of the patients before and after the procedure are summarized in Table 1. Accordingly, a statistically significant difference was found between the mean TSH values before and after the procedure (0.305 vs. 1.792; p < 0.01). On the other hand, no significant difference was found in fT3 and fT4 values after the procedure compared to the pre-procedure values.
Table 1.
Comparison of thyroid function tests before and after the procedure
| Pre-Processing* | After Procedure* | p | |
|---|---|---|---|
| TSH (mIU/L) | 0.305 (0.08–0.496) | 1.792 (0.06–26.8) | < 0.01† |
| fT4 (ng/L) | 1.309±0.280 | 1.303±0.326 | 0.439‡ |
| fT3 (ng/L) | 2.912±0.716 | 2.717±0.689 | 0.102‡ |
*Mean±SD for parametric tests; median (min-max) for nonparametric tests
† Wilcoxin signed rank test
‡ Paired t-test
In addition to the significant difference in TSH values after the procedure, especially in 2 pa-tients, TSH was detected as an extreme value at 20.3 and 26.8 mIU/L and these two patients were included in the group that developed marked hypothyroidism, and in one of the 2 patients who developed hyperthyroidism, T4 increased to 2.38 as an extreme value (Fig. 3).
Fig. 3.
Box plot comparing thyroid function tests before and after the procedure
When the patients were classified according to the amount of contrast medium they received, no significant difference was observed between the group exposed to high contrast volume and the group exposed to low contrast volume in terms of final thyroid function. Two patients with overt hyperthyroidism were also in the low contrast volume group, but this did not result in a statistically significant difference. Although one of the 2 patients with overt hypothyroidism was in the low contrast volume group and the other in the high contrast volume group, this did not cause a significant difference. Likewise, according to the results of two-way repeated ANOVA, it was observed that there was no significant difference between low and high contrast volume groups for TSH, fT4 and fT3 values before and after the procedure (Table 2).
Table 2.
Changes in thyroid function according to the iodinated contrast volume exposed
| Low Volume(n = 38) | High Volume (n = 8) | p | |
|---|---|---|---|
| After the procedure | |||
| Subclinical hyperthyroidism | 15 (39.5%) | 4 (50.0%) | 0.700 |
| Euthyroidism | 20 (52.6%) | 3 (43.5%) | 0.699 |
| Overt Hyperthyroidism | 2 (5.3%) | 0 (%0) | 1.000 |
| Hypothyroidism | 1 (2.6%) | 1 (12.5%) | 0.321 |
| TSH (mIU/L) | 0.226* | ||
| Pre-procedure | 0.159 (± 0.133) | 0.244 (± 0.196) | |
| Post-procedure | 0.397 (± 0.407) | 7.8 (± 10.885) | |
| fT4 (ng/L) | 0.087* | ||
| Pre-procedure | 1.355 (± 0.318) | 1.380 (± 0.441) | |
| Post-procedure | 1.305 (± 0.314) | 1.086 (± 0.425) | |
| fT3 (ng/L) | 0.378* | ||
| Pre-procedure | 2.82 (± 0.818) | 3.026 (± 0.707) | |
| Post-procedure | 2.747 (± 0.627) | 2.676 (± 0.912) |
* Two-way repeated ANOVA test
Discussion
In this study, we retrospectively analyzed the effects of ICM exposure on thyroid function in patients with subclinical hyperthyroidism. Our findings show that a significant proportion of patients with subclinical hyperthyroidism became euthyroid after the procedure, but some developed hypothyroidism and hyperthyroidism. It is very valuable that all of the patients included in our study were in the subclinical hyperthyroidism group. Because many studies on the subject in the literature were collected from euthyroid patient populations, or from pools of patients with and without thyroid dysfunction but with previously known thyroid disease [22]. Nygaard et al. Thyroid function was analyzed in 38 patients, 22 of whom had previously known thyroid disease (Graves’ disease, toxic nodular/multinodular goiter) at 1 week and 1 month after CT scan with 100 ml iohexol. Initial mean TSH values of 0.41 mIU/L (0.005-4.30) increased to 0.64 after 1 month and this value was found to be statistically significant (p = 0.03). 2 patients developed transient hypothyroidism, and 4 patients developed hyperthyroidism. Although these findings overlap with our study, they differ from our study in that there were no patients with baseline TSH values in the normal range. In addition, it should be taken into consideration that the patients who developed hyperthyroidism in the study of Nygaard et al. had a history of thyrotoxicosis and the amount of contrast administered was different [23].
Breuel et al. In their study with 39 euthyroid patients, they showed that there was a tendency towards hyperthyroidism in patients at 6 weeks and 6 months after ICM and that this effect became more pronounced at 6 months [24]. Özkan et al. showed that approximately 6% of 101 euthyroid patients developed subclinical hyperthyroidism at 4 and 8 weeks after coronary angiography [12]. Rhee et al. calculated a 2.5-fold increased risk of hyperthyroidism and a 3.05-fold increased risk of hypothyroidism after ICM [25]. When Bervini et al. evaluated the studies in terms of the risk of hyperthyroidism after ICM in their metanalysis including 30 studies, they did not consider this risk to be high but recommended close follow-up of selected patient groups [22]. Among all these studies, only Fricke et al. selected the subclinical hyperthyroidism group as the baseline patient population as in our study and decided on prophylaxis before coronary angiography based on the iodine uptake status of 91 patients using Technetium 99 m scintigraphic methods. No cases of hyperthyroidism were observed in the group not receiving prophylaxis, whereas two patients developed mild hyperthyroidism in the group receiving prophylaxis (iodine uptake >1%) [26]. However, the prognosis of this group in the absence of prophylaxis could not be predicted due to this intervention. At this point, the lack of intervention in our study was thought to provide more accurate results in this patient population due to its observational nature.
The risk of hypothyroidism after ICM has been discussed in many studies and some studies have reported a 2–3 fold risk [11, 14, 25, 27]. However, mild or subclinical hypothyroidism was observed in most of these studies. In our study, TSH values exceeding 20 mIU/L were observed especially in 2 patients. The fact that thyroid ultrasonographic imaging and autoantibody levels in terms of autoimmune thyroid diseases could not be evaluated in these patients because of the retrospective design of the study is one of the limitations of the study, but it was considered to be noteworthy in terms of the severity of hypothyroidism that may develop.
One of the strengths of the study was classification in terms of contrast volume. Previously, Chen et al. similarly classified 2062 euthyroid patients in terms of ICM volume and showed that the risk of developing thyroid dysfunction increased with increasing contrast volume as a composite endpoint [16]. A similar result could not be reached in our study, but the small number of patients in the high-volume group was considered as one of the limitations.
This study has several limitations. First, due to its retrospective design, detailed etiological evaluation such as thyroid autoantibody levels or scintigraphic imaging could not be performed. Second, the follow-up period was limited to one month, and long-term changes in thyroid function could not be assessed. Third, the relatively small number of patients, particularly in the high-contrast-volume group, may have limited the statistical power to detect subtle differences. Finally, since all participants were from an iodine-sufficient area, the results may not be directly generalizable to populations with different iodine intake status.
Despite these limitations, the study also has notable strengths. All patients were carefully selected from a homogeneous subclinical hyperthyroid population, minimizing baseline variability. The exclusive inclusion of angiography patients with well-documented pre- and post-procedural thyroid function tests adds robustness to the dataset. Moreover, by classifying patients according to contrast volume, this study provides a unique comparative perspective that has been rarely addressed in similar research. Overall, these strengths enhance the reliability of the findings and support their contribution to the existing literature.
When the results of the study are evaluated from a broad perspective, contrary to what was predicted in patients with subclinical hyperthyroidism, in whom clinicians had to be careful especially because of cardiovascular complications, thyroid functions were mostly either stable or euthyroid at 1 month after ICM. The shift of mean TSH values to the normal range after the procedure was found to be statistically highly significant (p < 0.01). This was independent of the amount of ICM exposed. In addition, although not statistically significant, 2 patients developed overt hyperthyroidism, and another 2 patients developed overt hypothyroidism. The necessity of determining the underlying thyroid pathologies in patients who are not known to receive any thyroid-related medication suggests that prospective studies for this patient population will shed light. In addition, it is believed that long-term follow-up will guide clinicians in terms of evaluating the persistence of measurements made at one-month intervals.
Conclusion
This study evaluated the effects of ICM exposure on thyroid function in patients with subclinical hyperthyroidism. Our findings show that the use of ICM in this patient group mostly stabilizes or improves thyroid function. However, since some patients may develop hyperthyroidism or hypothyroidism, such patients should be carefully monitored during and after ICM administration. Prospective studies with larger patient groups will contribute to a better understanding of these findings.
Acknowledgements
We would like to extend our gratitude to the entire staff of the cardiology clinic who were involved in the procedures and follow-up of the patients in this study. Their dedication and assistance were crucial in ensuring the successful completion of this research.
Author contributions
Z.E.D. and F.C. designed the study, collected patient data, analaysed data, wrote the main manuscript, reviewed and editted the manuscript equally.
Funding
No funding was received for this study.
Data availability
No datasets were generated or analysed during the current study.
Declarations
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Health Sciences University, Haydarpaşa Numune Education and Research Hospital, located in Istanbul, Turkey (Ethics Committee Approval No: 2023/67, Date: 30/05/2023). The need for informed consent was waived due to the retrospective nature of the study.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Weir-McCall JR, Williams MC, Shah AS, et al. National trends in coronary artery disease imaging: associations with health care outcomes and costs. Cardiovasc Imaging. 2023;16(5):659–71. [DOI] [PubMed] [Google Scholar]
- 2.Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics. 2004;24(suppl1):S3–10. 10.1148/rg.24si045519. [DOI] [PubMed] [Google Scholar]
- 3.Rose TA, Choi JW. Intravenous imaging contrast media complications: the basics that every clinician needs to know. Am J Med. 2015;128(9):943–9. 10.1016/j.amjmed.2015.02.018. [DOI] [PubMed] [Google Scholar]
- 4.World Health Organization. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers. World Health Organization. Published online 2007.
- 5.Meyers LD, Hellwig JP, Otten JJ. Dietary reference intakes: the essential guide to nutrient requirements. National Academies. 2006.
- 6.van der Molen AJ, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Effect of iodinated contrast media on thyroid function in adults. Eur Radiol. 2004;14:902–7. [DOI] [PubMed] [Google Scholar]
- 7.Wolff J, Chaikoff I. Plasma inorganic iodide as a homeostatic regulator of thyroid function. Published online 1948. [PubMed]
- 8.Wolff J, Chaikoff I, Goldberg R, Meier J. The temporary nature of the inhibitory action of excess iodide on organic iodine synthesis in the normal thyroid. Endocrinology. 1949;45(5):504–13. [DOI] [PubMed] [Google Scholar]
- 9.C JF. Nouvelles recherches Sur Les effets de l’iode et Sur Les précautions à Suivre Dans Le traitement du goître par Ce nouveau remède. Ann Chim Phys Ser 2. 1821;16:345–56. [Google Scholar]
- 10.Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metabolism. 2015;100(2):376–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kornelius E, Chiou JY, Yang YS, Peng CH, Lai YR, Huang CN. Iodinated contrast media increased the risk of thyroid dysfunction: A 6-Year retrospective cohort study. J Clin Endocrinol Metabolism. 2015;100(9):3372–9. 10.1210/JC.2015-2329. [DOI] [PubMed] [Google Scholar]
- 12.Özkan S, Oysu AS, Kayatas K, et al. Thyroid functions after contrast agent administration for coronary angiography: a prospective observational study in euthyroid patients/Koroner Anjiyografi Amaciyla Kontrast madde verildikten sonra tiroid fonksiyonlari: Ötiroid Hastalarda prospektif Bir gözlemsel çalisma. Anatol J Cardiol. 2013;13(4):363. [DOI] [PubMed] [Google Scholar]
- 13.Marraccini P, Bianchi M, Bottoni A, et al. Prevalence of thyroid dysfunction and effect of contrast medium on thyroid metabolism in cardiac patients undergoing coronary angiography. Acta Radiol. 2013;54(1):42–7. [DOI] [PubMed] [Google Scholar]
- 14.Gartner W, Weissel M. Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week? Thyroid. 2004;14(7):521–4. [DOI] [PubMed] [Google Scholar]
- 15.Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J. Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. European J Endocrinology Published Online March. 1999;1264–7. 10.1530/eje.0.1400264 [DOI] [PubMed]
- 16.Chen Y, Zheng X, Li N, et al. Impact of iodinated contrast media in patients received percutaneous coronary intervention: focus on thyroid disease. Front Endocrinol. 2022;13:917498. 10.3389/fendo.2022.917498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Rhee C, Lynch KE, Zandi-Nejad K, Pearce EN, Alexander EK, Brunelli SM. Iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism in a community-based cohort. Endocrinol Stud. 2013;3(2).
- 18.Donangelo I, Suh SY. Subclinical hyperthyroidism: when to consider treatment. Am Family Phys. 2017;95(11):710–6. [PubMed] [Google Scholar]
- 19.Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: A summary of the evidence for the U.S. Preventive services task force. Ann Intern Med. 2004;140(2):128. 10.7326/0003-4819-140-2-200401200-00015. [DOI] [PubMed] [Google Scholar]
- 20.Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012:172(10). 10.1001/archinternmed.2012.402 [DOI] [PMC free article] [PubMed]
- 21.Department of Endocrinology and Metabolism, Faculty AUM, Ankara, Turkey, Tan Öksüz SB, Erdoğan MF. Department of endocrinology and Metabolism, Ankara university medical Faculty, Ankara, Turkey. Current iodine status in Europe and Türkiye in the light of the world health organization European region 2024 report: are we losing. Our Achievements? ERP. 2025;29(2):140–8. 10.5152/erp.2025.24594. [Google Scholar]
- 22.Bervini S, Trelle S, Kopp P, Stettler C, Trepp R. Prevalence of iodine-induced hyperthyroidism after administration of iodinated contrast during radiographic procedures: a systematic review and meta-analysis of the literature. Thyroid. 2021;31(7):1020–9. [DOI] [PubMed] [Google Scholar]
- 23.Nygaard B, Nygaard T, Jensen LI, et al. Iohexol: effects on uptake of radioactive iodine in the thyroid and on thyroid function. Acad Radiol. 1998;5(6):409–14. 10.1016/S1076-6332(98)80026-3. [DOI] [PubMed] [Google Scholar]
- 24.Breuel H, Breuel C, Emrich D, Fischer P, Gilak A, Winkler C. Changes in thyroid function after application of iodinated contrast media to normal subjects (author’s transl). Med Klin. 1979;74(41):1492–6. [PubMed] [Google Scholar]
- 25.Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med. 2012;172(2):153–9. [DOI] [PubMed] [Google Scholar]
- 26.Fricke E, Fricke H, Esdorn E, et al. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low Thyrotropin. J Clin Endocrinol Metabolism. 2004;89(12):6092–6. [DOI] [PubMed] [Google Scholar]
- 27.Sohn SY, Inoue K, Bashir MT, et al. Thyroid dysfunction risk after iodinated contrast media administration: a prospective longitudinal cohort analysis. J Clin Endocrinol Metab. 2024 May 3;dgac304. 10.1210/clinem/dgae304 [DOI] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
No datasets were generated or analysed during the current study.



